InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
Rubius Therapeutics developed our proprietary RED PLATFORMÂŽ to generate red blood...
Rubius Therapeutics developed our proprietary R...
InMode Ltd. (Nasdaq: INMD) is a leading global provider of innovative medical tech...
InMode Ltd. (Nasdaq: INMD) is a leading global ...
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
We are a late stage biopharmaceutical company focused on the development and comme...
We are a late stage biopharmaceutical company f...
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...
Incyte Corporation is a Wilmington, Delaware-ba...
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...
Mersana Therapeutics is a clinical-stage biopha...
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...
Provention Bio, Inc. is a clinical-stage biopha...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Join the National Investor Network and get the latest information with your interests in mind.